NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Trefoil Therapeutics

Trefoil Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://trefoiltherapeutics.com/

Last Round

Series A

Extension

Mar 8, 2022

Total Funding Raised

$45.6M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Trefoil Therapeutics is a biotechnology company that develops regenerative pharmacologic treatments for corneal diseases using engineered fibroblast growth factor-1 protein technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

Fuchs DystrophyFECDcorneal transplant alternativeregenerative medicineFGF-1 therapycorneal disease treatmentbiologicscorneal cell regenerationcorneal endothelial dystrophyclinical-stage biotechintracameral injectiontopical eye dropengineered growth factorcorneal epithelial conditions

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Trefoil Therapeutics Comparables

Compare Trefoil Therapeutics with similar companies based on industry and business-model similarity.

Trefoil Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Emmecell
85%
ActualEyes, Inc.
79%
Alcon
77%

Trefoil Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMar 8, 2022
Series AJul 16, 2019
Series 1Jan 5, 2017
GrantOct 20, 2015

Trefoil Therapeutics Investors

Notable investors and investment history

Trefoil Therapeutics investors
InvestorRounds
Hatteras Venture PartnersSeries A, Series 1
Correlation VenturesSeries 1, Series A
InFocus Capital PartnersSeries 1, Series A
National Eye InstituteGrant
Access BiotechnologySeries A
AJU IB InvestmentSeries 1, Series A
Solasta VenturesSeries 1, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 78% MoM.

  • Jan 5, 2017

    $5.2M round led by Hatteras Venture Partners.

Trefoil Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Trefoil Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Trefoil Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range10
Year Founded2013
Last FundingMar 8, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.